Tumor Biol. (2014) 35:11871–11877 DOI 10.1007/s13277-014-2429-4
RESEARCH ARTICLE
Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients Didem Tastekin & Suleyman Kargin & Mehmet Karabulut & Naile Yaldız & Makbule Tambas & Necla Gurdal & Ali Murat Tatli & Deniz Arslan & Ali Fuat Kaan Gok & Faruk Aykan
Received: 11 July 2014 / Accepted: 31 July 2014 / Published online: 21 August 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract The synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with esophageal carcinoma (EC). SNCG levels were assessed immunohistochemically in cancer tissues from 73 EC patients. Median age was 57 (range, 29–78) years old. D. Tastekin (*) : F. Aykan Department of Medical Oncology, Oncology Institute, Istanbul University, 34390 Istanbul, Turkey e-mail: [email protected] S. Kargin Department of General Surgery, Necmettin Erbakan University, Konya, Turkey M. Karabulut Department of General Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey N. Yaldız Department of Pathology, Necmettin Erbakan University, Konya, Turkey M. Tambas : N. Gurdal Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey A. M. Tatli Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey D. Arslan Department of Medical Oncology, Erzurum Training and Research Hospital, Erzurum, Turkey A. F. K. Gok Department of General Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59 % had epidermoid carcinoma. More than half of the patients (61 %) had undergone operation where 57 % received adjuvant treatment including chemotherapy or chemotherapy plus radiotherapy. Median overall survival was 11.3 ± 1.8 months (95% confidence interval (CI): 7.7– 14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80 vs. 53 %; p=0.05 and inoperable 59 vs.32 %; p=0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis (p=0.01, p60 60 10 % of all cancer cells stained within the section) was graded as weak [1], moderate [2], or strong [3]. During evaluation, the weak and moderate degreed ones were determined as group 1 (negative), and those with moderate and strong degreed as group 2 (positive). Statistical analysis SPSS for Windows version 21.0 (SPSS Inc., Chicago, IL., USA) was employed for data analysis. Continuous variables were categorized using negative and positive groups as cut-off point. Relationship and comparisons of several clinical/ laboratory variables were evaluated via Pearson chi-square was used. Fisher’s exact test is used where Pearson chi-
Table 3 Univariate analysis of the survival
Variables
Age of patients >60
RESEARCH ARTICLE
Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients Didem Tastekin & Suleyman Kargin & Mehmet Karabulut & Naile Yaldız & Makbule Tambas & Necla Gurdal & Ali Murat Tatli & Deniz Arslan & Ali Fuat Kaan Gok & Faruk Aykan
Received: 11 July 2014 / Accepted: 31 July 2014 / Published online: 21 August 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract The synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with esophageal carcinoma (EC). SNCG levels were assessed immunohistochemically in cancer tissues from 73 EC patients. Median age was 57 (range, 29–78) years old. D. Tastekin (*) : F. Aykan Department of Medical Oncology, Oncology Institute, Istanbul University, 34390 Istanbul, Turkey e-mail: [email protected] S. Kargin Department of General Surgery, Necmettin Erbakan University, Konya, Turkey M. Karabulut Department of General Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey N. Yaldız Department of Pathology, Necmettin Erbakan University, Konya, Turkey M. Tambas : N. Gurdal Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey A. M. Tatli Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey D. Arslan Department of Medical Oncology, Erzurum Training and Research Hospital, Erzurum, Turkey A. F. K. Gok Department of General Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59 % had epidermoid carcinoma. More than half of the patients (61 %) had undergone operation where 57 % received adjuvant treatment including chemotherapy or chemotherapy plus radiotherapy. Median overall survival was 11.3 ± 1.8 months (95% confidence interval (CI): 7.7– 14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80 vs. 53 %; p=0.05 and inoperable 59 vs.32 %; p=0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis (p=0.01, p60 60 10 % of all cancer cells stained within the section) was graded as weak [1], moderate [2], or strong [3]. During evaluation, the weak and moderate degreed ones were determined as group 1 (negative), and those with moderate and strong degreed as group 2 (positive). Statistical analysis SPSS for Windows version 21.0 (SPSS Inc., Chicago, IL., USA) was employed for data analysis. Continuous variables were categorized using negative and positive groups as cut-off point. Relationship and comparisons of several clinical/ laboratory variables were evaluated via Pearson chi-square was used. Fisher’s exact test is used where Pearson chi-
Table 3 Univariate analysis of the survival
Variables
Age of patients >60
